Tracers / [90Y]Y-pentixather
[90Y]Y-pentixather
Also written as Pentixather; pentixather; [Y-90]Pentixather; PentixaTher; [Y-90]Y-PentixaTher
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 9
What it is
- Compound class
- Pentixather (CXCR4-targeted radiolabelled peptide)
- Target / mechanism
- CXCR4 (chemokine receptor-4) PMID 28529638
- Clinical application
- CXCR4-directed endoradiotherapy in relapsed/refractory hematologic malignancies (multiple myeloma, acute leukemia) prior to hematopoietic stem cell transplantation PMID 30850502
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 28529638 2017 Theranostics |
| — | — | — | — | — | — | 41706122 2026 Eur J Nucl Med Mol Imaging |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | — | — | — | Pentixather | 29290814 2018 Theranostics using a GRP® module (SCINTOMICS GmbH, Fürstenfeldbruck, Germany) |
| — | — | — | — | — | — | 42244984 2026 Theranostics |
| — | — | — | — | — | — | 40323995 2025 Clin Nucl Med |
| — | — | — | — | — | — | 30850502 2019 J Nucl Med |
| Scintomics GRP / GRP-3V Scintomics | vendor cassette | — | — | — | Pentixather | 29290814 2018 Theranostics using a GRP® module (SCINTOMICS GmbH, Fürstenfeldbruck, Germany) equipped with disposable single-use cassette kits |
| — | — | — | — | — | — | 26877786 2016 Theranostics |
| — | — | — | — | — | — | 26564323 2016 J Nucl Med |
Need this precursor?We can point you to suppliers for [90Y]Y-pentixather, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29290814: 'Synthesis of Pentixafor and Pentixather'. | Stage 28: added indication(s) onc-myeloma, onc-leukemia from consolidated missing-rubric review.